Stingray Therapeutics
PrivateLast Round
Grant
Nov 15, 2023
Est. Valuation
$37M
Total Funding Raised
$33.96M
Company Overview
Stingray Therapeutics is a biotechnology company that develops immunotherapies designed to treat various types of cancer by targeting the innate immune system.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Stingray Therapeutics Comparables
Compare Stingray Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Riboscience | 93% | |
| TXINNO Bioscience INC | 87% | |
| ImmuneSensor Therapeutics | 86% |
Stingray Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 15, 2023 | ||||
| Seed | Jan 23, 2023 | ||||
| Grant | Oct 14, 2022 | ||||
| Seed | Apr 5, 2022 | ||||
| Pre Seed | Aug 13, 2020 | ||||
Accelerator | Aug 29, 2018 |
Stingray Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| NIH RADx | Grant |
| Catalytic Impact Foundation | Seed |
| Cancer Prevention and Research Institute of Texas | Grant |
| Green Park & Golf Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 15, 2023
Secured $14M in grant funding.
- Jan 23, 2023
$3M round completed.
Stingray Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Stingray Therapeutics's valuation, stock price, and market status.
Is Stingray Therapeutics a public or private company?
Stingray Therapeutics is a private company.
What is the current stock price of Stingray Therapeutics?
Stingray Therapeutics is a private company, so its shares have no public market price. Caplight tracks Stingray Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Stingray Therapeutics worth (valuation)?
Stingray Therapeutics's valuation is estimated at $37.0M based on funding round data.
Can I buy Stingray Therapeutics stock?
Stingray Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Stingray Therapeutics's last funding round?
Stingray Therapeutics's most recent funding round was Grant on November 15, 2023.
Who are the main investors in Stingray Therapeutics?
Key investors in Stingray Therapeutics include NIH RADx, Cancer Prevention and Research Institute of Texas.
Will Stingray Therapeutics IPO soon?
No public IPO plans have been announced for Stingray Therapeutics.
How can I track Stingray Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Stingray Therapeutics's shares on secondary markets.